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LETTER TO THE EDITOR
ARE PRESCRIBING INDICATORS ESSENTIALLY
REPRESENTING THE FRAIL OLDER POPULATION?
To the Editor: Older populations have multiple comorbid
chronic diseases that require multiple treatments, which make
them the larger consumer of medications (1). As a person
grows older the ability to tolerate medications become poor due
to age-related changes in pharmacokinetics and
pharmacodynamics. The number of comorbidities increases
with age that leads to the increase in number of medication
prescribed which is associated with increased risk of adverse
drug events (ADEs), impaired mobility, morbidity,
hospitalization and death. However, while one person becomes
hale and healthy another, who had seemed just as healthy, starts
to weaken and slow down, often heading along a path that ends
up in a medical condition known as frailty (2). Frailty in older
population is well defined as a reduced ability to withstand
illness without loss of function. Frail older persons often have
multiple comorbidities with signs of impairment in activities of
daily living. Prescribing drugs for these vulnerable populations
is complex and potentially unsafe. Factors such as
polypharmacy, multiple comorbidities, age-related changes in
pharmacokinetics and pharmacodynamics and other functional
impairment in frail older people make pharmacotherapy a
complex issue. Prescribing physician should realize the fact that
complying with the evidence based clinical guidelines is
usually acceptable for patients with less comorbidity, but as the
patients’ clinical and functional states deteriorate leading to the
progression towards frailty and disability, the goals of care and
treatment targets need to be readjusted (3).
Worldwide, inappropriate prescribing in older population
has drawn a significant attention as a major public health
concern due to its direct correlation with morbidity, mortality
and wastage of health resources. Several criteria have been
developed worldwide to identify the instances of inappropriate
prescribing in older patients that addresses certain aspects of
medication prescribing such as indication, drug-drug
interactions, drug-disease interaction, drug duplication, under
prescribing. Inappropriate prescribing can be detected using
explicit (criterion-based) or implicit (judgment-based)
prescribing indicators. Explicit criteria are derived from expert
reports or published reviews. They have high reliability and
reproducibility but focuses mainly on specific drugs and the
disease state. In contrast, implicit criteria are person specific
that explores patient preferences, rather than disease and
medications they rely on evaluator judgment and may have low
reliability and low practical utility (4).
Unfortunately, there appear no specific criteria for assessing
appropriateness of therapy in frail older patients. The guides
and criteria currently available are applicable to robust, healthy
older adults aged 65 and older which can’t be generalized in to
frail patients (2). In several instances prescribing is better
guided by outcomes from randomized controlled trails, which
are mainly targeted to robust elder patients while the typical
frail older are excluded (1). Only few proportions of
randomised, controlled trials and meta-analyses are published
about people over 65 years of age because older people are
rarely involved into clinical trials. For example, 37% of all
patients with acute myocardial infarctions are older than 75
years of age; however this age group only represents 2–9% of
clinical trial subjects (5). This discrepancy should be addressed
either by developing new criteria or by refining the existing
tools to be applicable in frail older people. These tools support
the prescribing practices and improve the overall well-being of
patients (6). The first and foremost step is to identify the frail
patients in clinical practice by developing a clinically validated
tool. Once, the frail patients are identified, there is a need of a
specific measures or a criteria to assess appropriateness of
therapy that considers patients quality of life, functional status,
remaining life expectancy and goal of care with optimal choice
of drug with the paramount risk-benefit ratio.
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